Impact of age, phenotype and cardio-renal function on plasma C-type and B-type natriuretic peptide forms in an adult population

Clinical Endocrinology

Volumn 78, Issue 5, 2013, Pages 783-789

  Prickett, T C R ^a   Olney, R C ^b   Cameron, V A ^a   Ellis, M J ^c   Richards, A M ^a   Espiner, E A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Nemour Children's Clinic   (United States)

^c Canterbury Health Laboratories Endolab   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BRAIN NATRIURETIC PEPTIDE; CREATININE; NATRIURETIC PEPTIDE TYPE C;

ADULT; AGE; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BONE TURNOVER; CARDIOVASCULAR RISK; COMORBIDITY; CREATININE BLOOD LEVEL; FEMALE; GENDER; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; MALE; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84876133077     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12035     Document Type: Article

References (41)

1. Takei, Y., Inoue, K., Trajanovska, S., et al,. (2011) B-type natriuretic peptide (BNP), not ANP, is the principal cardiac natriuretic peptide in vertebrates as revealed by comparative studies. General and Comparative Endocrinology, 171, 258-266.
2. Potter, L.R., Abbey-Hosch, S., &, Dickey, D.M., (2006) Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocrine Reviews, 27, 47-72.
3. Prickett, T.C.R., Lynn, A.M., Barrell, G.K., et al,. (2005) Amino-terminal proCNP: a putative marker of cartilage activity in postnatal growth. Pediatric Research, 58, 334-340.
4. Prickett, T.C., Dixon, B., Frampton, C., et al,. (2008) Plasma amino-terminal pro C-type natriuretic peptide in the neonate: relation to gestational age and postnatal linear growth. Journal of Clinical Endocrinology and Metabolism, 93, 225-232.
5. Olney, R.C., Prickett, T.C., Yandle, T.G., et al,. (2007) Amino-terminal propeptide of C-type natriuretic peptide and linear growth in children: effects of puberty, testosterone and growth hormone. Journal of Clinical Endocrinology and Metabolism, 92, 4294-4298.
6. Olney, R.C., Permuy, J.W., Prickett, T.C.R., et al,. (2012) Amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) predicts height velocity in healthy children. Clinical Endocrinology (Oxford), 77, 416-422.
7. Chusho, H., Tamura, N., Ogawa, Y., et al,. (2001) Dwarfism and early death in mice lacking C-type natriuretic peptide. Proceedings of the National Academy of Sciences of the United States of America, 98, 4016-4021.
8. Prickett, T.C., Bothwell, J.C., Yandle, T.G., et al,. (2012) Pharmacodynamic responses of plasma and tissue C-type natriuretic peptide to GH: correlation with linear growth in GH-deficient rats. Journal of Endocrinology, 212, 217-225.
9. Palmer, S.C., Prickett, T.C., Espiner, E.A., et al,. (2009) Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension, 54, 612-618.
10. Suga, S., Nakao, K., Itoh, H., et al,. (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". Journal of Clinical Investigation, 90, 1145-1149.
11. Prickett, T.C.R., &, Espiner, E.A., (2012) C-type Natriuretic Peptide (CNP) and postnatal linear growth. In Handbook of Growth and Growth Monitoring in Health and Disease (ed., V.R. Preedy,). Springer, NY, USA, pp. 2789-2809.
12. Del Ry, S., Cabiati, M., Stefano, T., et al,. (2011) Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients. Regulatory Peptides, 166, 15-20.
13. Vlachopoulos, C., Ioakeimidis, N., Terentes-Printzios, D., et al,. (2010) Amino-terminal pro-C-type natriuretic peptide is associated with arterial stiffness, endothelial function and early atherosclerosis. Atherosclerosis, 211, 649-655.
14. Koch, A., Voigt, S., Sanson, E., et al,. (2011) Prognostic value of circulating amino-terminal pro-C-type natriuretic peptide in critically ill patients. Critical Care (London, England), 15, R45.
15. Schouten, B.J., Prickett, T.C., Hunt, P.J., et al,. (2012) C-Type natriuretic peptide forms in adult hyperthyroidism: correlation with thyroid hormones and markers of bone turnover. Clinical Endocrinology, 76, 790-796.
16. Schouten, B.J., Prickett, T.C., Hooper, A.A., et al,. (2011) Central and peripheral forms of C-type natriuretic peptide (CNP): evidence for differential regulation in plasma and cerebrospinal fluid. Peptides, 32, 797-804.
17. Yandle, T.G., Richards, A.M., Gilbert, A., et al,. (1993) Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. Journal of Clinical Endocrinology and Metabolism, 76, 832-838.
18. Hunt, P.J., Richards, A.M., Nicholls, M.G., et al,. (1997) Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clinical Endocrinology, 47, 287-296.
19. Levey, A.S., Bosch, J.P., Lewis, J.B., et al,. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine, 130, 461-470.
20. Cole, T.J., (1990) The LMS method for constructing normalized growth standards. European Journal of Clinical Nutrition, 44, 45-60.
21. McDowell, M.A., Fryar, C.D., Ogden, C.L., et al,. (2008) Anthropometric reference data for children and adults: United States, 2003-2006. National Health Statistics Reports, 10, 1-45.
22. Hunt, P.J., Richards, A.M., Espiner, E.A., et al,. (1994) Bioactivity and metabolism of C-type natriuretic peptide in normal man. Journal of Clinical Endocrinology & Metabolism, 78, 1428-1435.
23. Kalra, P.R., Clague, J.R., Bolger, A.P., et al,. (2003) Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation, 107, 571-573.
24. Del Ry, S., Passino, C., Maltinti, M., et al,. (2005) C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. European Journal of Heart Failure, 7, 1145-1148.
25. Del Ry, S., Cantinotti, M., Cabiati, M., et al,. (2012) Plasma C-type natriuretic peptide levels in healthy children. Peptides, 33, 83-86.
26. Seibel, M.J., (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clinical Biochemist Reviews, 26, 97-122.
27. Olney, R.C., Bukulmez, H., Bartels, C.F., et al,. (2006) Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. Journal of Clinical Endocrinology and Metabolism, 91, 1229-1232.
28. Lango Allen, H., Estrada, K., Lettre, G., et al,. (2010) Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature, 467, 832-838.
29. MacArthur, D.G., Balasubramanian, S., Frankish, A., et al,. (2012) A systematic survey of loss-of-function variants in human protein-coding genes. Science, 335, 823-828.
30. Paajanen, T.A., Oksala, N.K., Kuukasjarvi, P., et al,. (2010) Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis. European Heart Journal, 31, 1802-1809.
31. Komatsu, Y., Itoh, H., Suga, S.I., et al,. (1996) Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells: role of the vascular natriuretic peptide system in vascular growth inhibition. Circulation Research, 78, 606-614.
32. Wang, Y., de Waard, M.C., Sterner-Kock, A., et al,. (2007) Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. European Journal of Heart Failure, 9, 548-557.
33. Ellis, K.L., Newton-Cheh, C., Wang, T.J., et al,. (2011) Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. Journal of Molecular and Cellular Cardiology, 50, 695-701.
34. Obineche, E.N., Pathan, J.Y., Fisher, S., et al,. (2006) Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney International, 69, 152-156.
35. Charles, C.J., Espiner, E.A., Richards, A.M., et al,. (1996) Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. American Journal of Physiology-Regulatory Integrative & Comparative Physiology, 270, R1324-R1331.
36. Del Ry, S., Cabiati, M., Vozzi, F., et al,. (2011) Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides, 32, 1713-1718.
37. Redfield, M.M., Rodeheffer, R.J., Jacobsen, S.J., et al,. (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology, 40, 976-982.
38. Wang, T.J., Larson, M.G., Levy, D., et al,. (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation, 109, 594-600.
39. Bayes-Genis, A., Lloyd-Jones, D.M., van Kimmenade, R.R., et al,. (2007) Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Archives of Internal Medicine, 167, 400-407.
40. Parmar, K.M., Larman, H.B., Dai, G., et al,. (2006) Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2. Journal of Clinical Investigation, 116, 49-58.
41. Wu, C., Wu, F., Pan, J., et al,. (2003) Furin-mediated processing of pro-C-type natriuretic peptide. Journal of Biological Chemistry, 278, 25847-25852.